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OBJECTIVES: The UCLA Prostate Cancer Index (UCLA-PCI) is
a disease speciﬁc Health-related Quality of Life (HRQOL)
measure used in early stage prostate cancer patients. We exam-
ined the UCLA-PCI’s measurement properties in this study.
METHODS: We systematically identiﬁed all published papers
citing the original publication using the Science Citation Index.
For completeness, we also searched the PubMed and Ovid data-
bases from 1995 to the present. We analyzed all English articles
reporting measurement properties of the UCLA-PCI. RESULTS:
We identiﬁed 224 papers. Seventy-seven of these papers reported
results using the UCLA-PCI in either cross-sectional designs (43)
or in longitudinal analyses (34). The UCLA-PCI exhibited high
reliability (intraclass correlation coefﬁcients ranged from 0.66 to
0.97). The UCLA-PCI also had good face and content validity,
as demonstrated by the number of studies that incorporated the
instrument and by its translation into ﬁve other languages. The
construct validity of the UCLA-PCI’s functioning domains has
been demonstrated with correlations of 0.42 to 0.88 when com-
pared with other relevant disease-speciﬁc HRQOL measures;
however further study comparing the UCLA-PCI to other
disease-speciﬁc HRQOL measures (FACT-P, EORTC-P, IPSS)
may be warranted. Although this instrument has been used in
many longitudinal research designs, its evaluative validity only
was assessed in one study (effect sizes ranged from 0.77 to 1.51).
The responsiveness of the UCLA-PCI to HRQOL changes has
been shown in many studies usually by comparing changes in the
study population with the UCLA-PCI values of older men
without prostate cancer (reported in 1999). To maximize inter-
pretability of each domain, both anchor and distributional tech-
niques should be utilized to determine what changes the patient
may perceive as minimally important differences. CONCLU-
SIONS: Although the UCLA-PCI has been shown to be reliable
and valid, we encourage further research establishing its inter-
pretability and expanding its validity through its assessment in
clinical trials.
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OBJECTIVES: To identify the most appropriate instruments
which could be used to assess health-related quality of life
(HRQoL) on the full-spectrum of human papillomavirus (HPV)
related cervical disease, namely HPV infection, cervical screen-
ing, pre-cancer and cancer. METHODS: Electronic databases
(PsycINFO, EMBASE, and PUBMED), the internet, and confer-
ence proceeding abstracts were searched. The impact of the
health states on HRQoL domains was documented and each
instrument was reviewed according to its domain coverage,
assessment features, and psychometric properties. RESULTS:
The search strategy produced 1011 articles. Of these 94 reported
HRQoL data, of which 53 used multidimensional HRQoL
instruments. Results indicated that HPV infection, screening, cer-
vical precancer and cancer have a direct and sizeable effect on
HRQoL, although not all domains were impacted per health
state. Overall, 24 different instruments were identiﬁed and cat-
egorised as follows: generic (8), illness-speciﬁc (2), cancer spe-
ciﬁc (5), psychosocial (5), or screening instruments (4). A review
of the instruments suggest that the Medical Outcomes Study
Short Form Health Survey (SF-36)would be most appropriate
generic HRQoL instrument which could be used in any health
state, and the European Organisation for Research and Treat-
ment of Cancer Core Quality of Life Questionnaire (EORTC-
QLQ-C30) would be the most suitable HRQoL cancer-speciﬁc
instrument in cervical cancer. Either the Psychosocial Effects of
Abnormal Pap Smears Questionnaire (PEAPS-Q) or the Cervical
Dysplasia Distress Questionnaire (CDDQ) could be used to
assess psychosocial impact in cervical dysplasia, and either the
Quality of Life for Population Screening (SCREENQOL) or the
Self-Evaluation Quality of Life Questionnaire (SEQOL) could 
be used as a screening instrument. CONCLUSIONS: There 
was no single instrument that covered all the domains that would
be directly relevant to each health state. Thus, our recommen-
dation is that when possible a battery of instruments including
one from each category identiﬁed should be administered in any
study.
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OBJECTIVE: Given a paucity of validity data for the EQ-5D in
cancer patients, we investigated its psychometric properties and
its ability to differentiate clinically different groups in patients
with advanced NSCLC. METHODS: The EQ-5D index and
Visual Analog Scale (VAS) were administered within a phase II
trial of combination chemotherapy over 6 months (at baseline,
start of each 3-week cycle, and end of patient’s last cycle). Clin-
ical assessments included radiological tumor response and
Eastern Cooperative Oncology Group performance status (PS).
Reliability was assessed using Cronbach’s a (internal consistency)
and Pearson correlation (test-retest). Analysis of variance
assessed construct validity. Effect size (ES) and standardized
response mean (SRM) were calculated to evaluate responsiveness
to change in clinical indicators. RESULTS: Data from 195
patients were analyzed. Cronbach’s a for EQ-5D index was 0.68
at baseline. Correlations for test-retest (mean = 7 days between
assessments) were 0.70 and 0.80 for the index and VAS, respec-
tively. Index and VAS scores differentiated patients by PS at all
assessments (p < 0.05), demonstrating construct validity. Mean
index scores were 0.73 (complete or partial response [CR/PR], n
= 42), 0.68 (stable disease [SD], n = 90), and 0.58 (progressive
disease [PD], n = 32). Index scores were signiﬁcantly lower in
patients with PD, compared to those with CR/PR (p = 0.047),
while VAS scores showed no signiﬁcant differences. ES and SRM
for index change scores were: 1) -0.73 and -0.38, respectively,
in patients whose PS worsened; -0.08 each in patients with stable
PS at the beginning of cycle 6; and 2) -0.27 and -0.38, respec-
tively, in patients with CR/PR; -0.36 and -0.34, respectively, in
patients with SD; -0.44 and -0.28, respectively, in patients with
PD. CONCLUSIONS: The EQ-5D was reliable and valid in
NSCLC. EQ-5D scores differentiated patients by performance
status and best tumor response, which is important for generat-
ing utilities associated with health states deﬁned by these clini-
cal indicators.
